Tele: 561.316.3330
Breaking Medical Device News

Thursday, September 23, 2021
HomeSpinalCyteSpinalCyte Announces Issuance of New Chondrocyte Patents in the U.S. and Japan

SpinalCyte Announces Issuance of New Chondrocyte Patents in the U.S. and Japan

SpinalCyte, LLC, a Texas-based regenerative medicine company focused on regrowth of the spinal disc using Human Dermal Fibroblasts (HDFs), today announced the issuance of new patents in the U.S. and Japan. The company’s patent portfolio now includes 39 U.S. and international patents issued with 100+ patents pending focused on the clinical use of fibroblasts. The company received IND clearance from the FDA in November to continue clinical trials into its lead fibroblast cell therapy product, CybroCell, in the treatment of degenerative disc disease.

“Our new patents demonstrate the versatility of our technology to repair cartilage not just in the spine, but throughout the body,” said Pete O’Heeron, Chief Executive Officer of SpinalCyte. “As the leader in the field of human dermal fibroblast therapy, we are excited to continue our clinical work to demonstrate the promise of HDFs for a variety of disease paths.”

The U.S. Patent No. 10,206,954 titled “Adipose Cells for Chondrocyte Applications,” and Japanese Patent No. 6456826 titled “Generation of Cartilage Ex Vivo From Fibroblasts” describe methods to differentiate adipose and fibroblast cells into cartilage using a mold to shape the tissue to replace damaged cartilage. Claims also include using a mixture of chondrocyte-like cells, adipose cells and growth factors delivered to a joint to repair damaged cartilage.

Degenerative disc disease (DDD) is a condition in which a patient’s spinal disc breaks down and can begin to collapse. It is estimated that 85% of people over the age of 50 have evidence of disc degeneration and over 1.3 million procedures a year are performed to treat the disease. The most common treatments for patients with DDD are either discectomy or spinal fusion. Discectomy is the partial or full removal of the degenerated disc to decompress and relieve the nervous system but can cause long term spinal pain. In a spinal fusion procedure, the entire disc is removed and the two adjacent vertebrae are fused together. It often increases strain on the adjacent discs and surrounding tissues leading to further degeneration.

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Stay Connected

spot_img

Don't Miss

Kleiner Device Labs Receives FDA Market Clearance for KG2 Surge Flow-Thru Interbody System

The system maximizes total bone graft delivery volume, better distributes graft bilaterally into the intervertebral disc space, and streamlines the implant delivery, positioning, and grafting process for TLIF and PLIF spinal fusion procedures.

Matthew Cranfill New ExtriCARE USA Director Of Clinical Services

"Matt's impressive experience and skillset easily made him our top pick," said Peter Mason, President of ExtriCARE USA.

FDA Authorizes Software that Can Help Identify Prostate Cancer

The software is called Paige Prostate and is compatible for use with slide images that have been digitized using a scanner.

Shannon Lantzy MedCrypt New VP of Consulting

"I met Shannon at a healthcare-related event several years ago and was immediately impressed with her passion and drive to move healthcare into a digital future," said Mike Kijewski, CEO of MedCrypt.

Mark Foster Joins Xenocor BOD

Foster is a versatile and visionary C-Suite executive who brings 20 years of general management and leadership experience from both venture-backed growth-stage organizations and world-class medical device companies

Hinge Health Acquires the Most Advanced Computer Vision Technology for Tracking Human Motion

CEO Daniel Perez explained, “We won’t stop investing in technology to deliver the most patient-centered digital clinic that improves member experience and outcomes while reducing costs. wrnch allows us to take a giant leap forward in all respects.”

Dale W Wood Congratulates the Huma Team on Raising $130 Million

Major health and technology companies across the world have committed upwards of $130 million to Huma Therapeutics, the health-tech company backed by Dale Ventures.

Rhaeos Awarded $4 Million NIH SBIR Grant

Under the NIH SBIR grant, Rhaeos will leverage their existing wireless sensor hardware to provide additional quantitative flow data to the clinician, giving insight into this currently inaccessible and highly relevant shunt performance metric.

By using this website you agree to accept Medical Device News Magazine Privacy Policy